PERSISTENCE OF BCR/ABL MESSENGER-RNA-EXPRESSING BONE-MARROW CELLS IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN COMPLETE CYTOGENETIC REMISSION INDUCED BY INTERFERON-ALPHA THERAPY

被引：5

作者：

EBERLE, F ^{[1
]}

TOIRON, Y ^{[1
]}

CAMERLO, J ^{[1
]}

LAFAGE, M ^{[1
]}

SAINTY, D ^{[1
]}

ARNOULET, C ^{[1
]}

RAINERI, V ^{[1
]}

GABERT, J ^{[1
]}

MARANINCHI, D ^{[1
]}

MANNONI, P ^{[1
]}

机构：

[1] INST PAOLI CALMETTES,DEPT MOLEC & CELL BIOL,MARSEILLE,FRANCE

来源：

LEUKEMIA & LYMPHOMA | 1995年 / 18卷 / 1-2期

关键词：

INTERFERON-ALPHA; CHRONIC MYELOGENOUS LEUKEMIA; MINIMAL RESIDUAL DISEASE;

D O I：

10.3109/10428199509064936

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Complete hematologic and cytogenetic responses can be obtained with interferon-a (IFN-a) in 15-25% of the patients with chronic myelogenous leukemia (CML). In these patients, reverse-transcription polymerase chain reaction (RT-PCR) can be used to evaluate minimal residual disease. We studied 12 patients who remained Philadelphia-negative for a median period of 21 months on IFN-alpha therapy. Using RT-PCR, the specific transcript was found in all bone marrow (BM) samples. Ten patients still exhibiting a persistent residual clone remained in cytogenetic remission for a median period of 14 months. As we observed a dissociation between bcr-abl expression in BM and peripheral blood (PB) cells, and given the known fluctuations of the bcr-abl PCR results, we suggest that PB negative results should be confirmed on BM specimens. Alternatively, it remains to be demonstrated whether longitudinal monitoring of residual disease would benefit from quantitative PCR or double fluorescence in situ hybridization.

引用

页码：153 / 157

页数：5

共 33 条

[1] Kurzrock R., Gutterman J., Talpaz M., The molecular genetics of Philadelphia chromosome-positive leukemias, NEIM, 319, pp. 990-998, (1988)
[2] McGlave P., Bone marrow transplants in chronic myelogenous leukemia: an overview of determinants of survival, Sem. Hematol, 27, pp. 23-30, (1990)
[3] Bertheas M.F., Lafage M., Levy P., Blaise D., Stoppa A., Viens P., Mannoni P., Maraninchi D., Influence of mixed chimerism on the results of allogeneic bone marrow transplantation for leukemia, Blood, 78, pp. 3103-3106, (1991)
[4] Maraninchi D., Gluckman E., Blaise D., Guyotat D., Rio B., Pico J.L., Leblond V., Michallet M., Dreyfus I.N., Bordigoni A., Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukemias, The Lancet, 2, pp. 175-178, (1987)
[5] Talpaz M., Kantarjian H., Kurzrock R., Trujillo J., Gutterman J., Interferon alpha produces sustained cytogenetic responses in chronic myelogenous leukemia, Ann. Intern. Med, 114, pp. 532-538, (1991)
[6] Morra E., Lazzarino M., Alimena G., Liberati A., Grignani F., Mandelli F., Bernasconi C., The role of interferon in the treatment of chronic myelogenous leukemia results and prospects, Leukemia & Lymphoma, 6, pp. 305-315, (1992)
[7] Arcese W., Mauro F.R., Screnci M.A., Alimena G., Iori A.P., De Cuia M., Lo Coca F., Montefusco E., Fazi P., Mandelli F., Alpha-2b-interferon as single therapy for patients with chronic myeloid leukemia relapsing after T-cell depleted allogeneic bone marrow transplantation, European J. Haematol, 45, pp. 36-39, (1990)
[8] Gabert J., Thuret I., Lafage M., Carcassonne Y., Maraninchi D., Mannoni P., Detection of residual ber/abl translocation by polymerase chain reaction in chronic myeloid leukemia patients after bone marrow transplantation, The Lancet, 2, pp. 1225-1228, (1989)
[9] Chirgwin J., Przybyla A., MacDonald R., Rutter W., Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease, Biochem, 18, pp. 5294-5299, (1979)
[10] Kawasaki E.S., Clark S.S., Coyne M.Y., Smith S.D., Champlin R., Witte O.N., McCormick F.P., Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro, Proc. Natl. Acad. Sci. USA, 85, pp. 5698-5702, (1988)

← 1 2 3 4 →